Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue
NCT05378100Phase 2Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Jan 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in multiple sclerosis (MS) (3 arms), sponsored by Johns Hopkins University. Primary endpoint: Modified Fatigue Impact Scale at 4 weeks. Started Jan 2023; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05378100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378100.